TY - JOUR
T1 - Strategies for development of potential candidate Shigella vaccines
AU - Lindberg, Alf A.
AU - Pál, Tibor
N1 - Funding Information:
Work reported in this review and carried out in the authors' laboratories was supported by the Swedish Medical Research Council (grant No. 16X-656), the Swedish Agency for Research Cooperation with Developing Countries (SAREC) and the Sigurd and Elsa Goljes Foundation.
PY - 1993
Y1 - 1993
N2 - Bacillary dysentery, caused by Shigella bacteria, is a major enteric disease responsible for over 200 million infections annually with 650 000 fatal cases. Due to its high communicability, improvement of hygienic standards alone should reduce the spread of dysentery. However, such measures are expensive, and in the communities (e.g. penitentiaries and asylums) or in the areas of the world where bacillary dysentery is most frequently encountered (e.g. in the developing countries) they are not likely to take effect in the reasonably near future. Therefore the possibility of other preventive means such as anti-dysentery vaccines have been explored over the past 40 years. Recently, increased understanding of the molecular biology of bacillary dysentery and the possibility of designing well characterized vaccine strains have increased interest in the field. Several promising vaccine candidates are at various levels of investigations, but to date no Shigella vaccines are available for public health purposes. In this review, beyond the relevant basic information about the pathology, pathomechanism and molecular biology of bacillary dysentery, the various approaches and strategies to construct a safe and immunogenic anti-dysentery vaccine are critically discussed.
AB - Bacillary dysentery, caused by Shigella bacteria, is a major enteric disease responsible for over 200 million infections annually with 650 000 fatal cases. Due to its high communicability, improvement of hygienic standards alone should reduce the spread of dysentery. However, such measures are expensive, and in the communities (e.g. penitentiaries and asylums) or in the areas of the world where bacillary dysentery is most frequently encountered (e.g. in the developing countries) they are not likely to take effect in the reasonably near future. Therefore the possibility of other preventive means such as anti-dysentery vaccines have been explored over the past 40 years. Recently, increased understanding of the molecular biology of bacillary dysentery and the possibility of designing well characterized vaccine strains have increased interest in the field. Several promising vaccine candidates are at various levels of investigations, but to date no Shigella vaccines are available for public health purposes. In this review, beyond the relevant basic information about the pathology, pathomechanism and molecular biology of bacillary dysentery, the various approaches and strategies to construct a safe and immunogenic anti-dysentery vaccine are critically discussed.
KW - Shigella
KW - bacillary dysentery
KW - development
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=0027511196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027511196&partnerID=8YFLogxK
U2 - 10.1016/0264-410X(93)90014-O
DO - 10.1016/0264-410X(93)90014-O
M3 - Article
C2 - 8438615
AN - SCOPUS:0027511196
SN - 0264-410X
VL - 11
SP - 168
EP - 179
JO - Vaccine
JF - Vaccine
IS - 2
ER -